We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Growth treatment

7 October 2005 By Simon Nixon

That was always likely, given the huge interest Boots Healthcare attracted. But it doesn’t mean that Reckitt will suffer the winner’s curse. The deal makes strategic sense, there are synergies and Reckitt has strong management. Investors should give it the benefit of the doubt.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)